Featured content
Why better technology does not always lead to better R&D decisions
Making better decisions in drug discovery is not down to implementing more tools. Here, Dr Harsh Shah reveals why teams must start by defining the scientific question.
ArticleHow asymmetric binding affinity enables reversible IL-12 switches
Stronger binding isn’t always better. Dr Teresa Barata of FairJourney Bio explains how researchers engineered a dual-specificity antibody switch designed to control IL-12 activity in tumours.
ArticleWhat tissue accumulation can reveal about oligonucleotide safety
Oligonucleotides can remain in tissues long after disappearing from circulation, but does accumulation necessarily indicate toxicity? Dr Tina Rogers examines the evidence needed to interpret preclinical safety findings.
ArticleStrong binding isn’t enough – why cellular target engagement matters
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
News
NewsAlzheimer’s risk gene CASS4 found to regulate microglial immune response
Researchers at the University of Virginia Health have uncovered a previously unknown role for the Alzheimer’s risk gene CASS4 in controlling microglial activity, suggesting that restoring its function could offer a novel strategy for slowing disease progression.
NewsPsychedelics and cancer: exploring neurological pathways in tumour biology
A new peer-reviewed review explores whether psychedelic compounds could influence cancer biology through neurological and immune mechanisms, whilst identifying psychological wellbeing as the most credible near-term clinical opportunity.
NewsDNA enhancer switch drives androgen receptor breast cancer suppression
A small regulatory DNA element called HRRINT3 has been found to play a critical role in enabling the androgen receptor to suppress cell growth in oestrogen receptor-positive breast cancer, pointing towards new therapeutic strategies for patients with advanced disease.
NewsCell reprogramming induces immune structures across seven cancer types
Asgard Therapeutics has shown that its in vivo cell reprogramming platform can reliably induce mature immunogenic tertiary lymphoid structures across seven tumour types.
From our partners
Report
Lab Automation 2026: Inside the labs making drug discovery faster and more reliable
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Opinion and interviews
How multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
What it really takes to turn cancer discoveries into new therapies
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
From vial to viable: best practices for culturing organoids
On-demand Webinars
- Previous
- Next
